Meeting Coverage

Meeting Coverage

video

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin...

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
video

Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also...
video

Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab Improve Survival in...

Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response...
video

James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma

Dr. Kochenderfer reports "very exciting" results from bb121, a new BCMA-targeting CAR T-cell therapy for treating patients with heavily pretreated myeloma, trending towards less...
video

Yazan F. Madanat, MD: How Does Smoking Increase MDS Risk?

Smoking is associated with an increased risk of developing mutations that lead to myelodysplastic syndromes, but the associationg changes with patients' smoking patterns. Dr....
video

Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL

Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma -...
video

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

Replacing bleomycin with brentuximab vedotin in standard ABVD therapy led to a "modest improvement" in outcomes for patients with Hodgkin lymphoma, without increased long-term...
video

Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS

Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute...
video

Gerald A. Soff, MD: Examining a New Indication for Romiplostim

Dr. Soff discusses results from a phase II study of romiplostim in treating patients with chemotherapy-induced thrombocytopenia. The agent led to high rates of...
video

Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML

Patients with myelodysplastic syndromes and chronic myelomonocytic leukemia and TET2 mutations have high risks of cardiovascular toxicity, suggesting that these patients might benefit from...
Advertisement

Current Issue

December 2017, Volume 3, Issue 14

This issue features physicians' insights on gun control, the use of cannabis for symptom relief, and more.